AB Science has received a patent in Japan covering the use of its investigational oral therapy masitinib for progressive forms of multiple sclerosis (MS). The new patent — JP 7788154 — grants the France-based pharmaceutical company protection in the Asian nation through February 2041 on the use of masitinib…
Treatment with the nasal spray therapy foralumab stabilized disability over six months in all 10 people with nonactive secondary progressive multiple sclerosis (SPMS) who took part in an expanded access program, according to a peer review. For those who received treatment for at least one year, the majority experienced…
Discussion
Self-care is often framed as something luxurious, such as spa days, vacations, quiet mornings with coffee, and a to-do list that magically completes itself. But self-care looks different for everyone, especially those who are navigating chronic stress, illness, or caregiving. Living with relapsing-remitting multiple sclerosis, I’ve learned that self-care…
Bionxt Solutions’ experimental sublingual therapy BNT23001 led to about 40% higher blood exposure to cladribine than a conventional oral tablet formulation, such as those used in multiple sclerosis (MS) therapies like Mavenclad, the company reported. The results come from a preclinical study in adult miniature pigs,…
When immune B-cells mistakenly recognize the body’s own nerve tissue, they can shut themselves down to prevent damage, but infection with the Epstein-Barr virus (EBV) can trick B-cells into surviving and becoming activated in the brain instead of being eliminated by normal immune safety mechanisms, according to a study.
Get regular updates to your inbox.
